Summit Therapeutics(NASDAQ) SMMT

Summit helps doctors treat serious cancers by making a new kind of medicine. These treatments aim to help people live longer while feeling better during their care. The company focuses on specific types of lung and colon cancer.

Fighting Cancer with Bispecific Technology

• Ivonescimab: Potential first-in-class bispecific antibody that blocks both PD-1 and VEGF-A proteins to stop tumor growth and blood supply; currently in Phase III trials for lung and colorectal cancer.
• Ridinilazole: Orally administered small molecule antibiotic; currently in Phase III clinical trials to treat Clostridioides difficile, an infection that causes severe diarrhea and colon inflammation.
• SMT-738: Research-stage treatment for multidrug resistant infections; designed to combat bacteria that have become resistant to standard carbapenem antibiotics.
• DDS-04 Series: Early-stage development program; focuses on treating infections caused by the Enterobacteriaceae family of bacteria.

Strategic Partnerships and Expansion

• In-licensed rights to develop and sell ivonescimab in North America, Europe, and Japan through a January 2023 agreement with Akeso.
• Expanded the Akeso licensing agreement in June 2024 to include rights for Latin America, the Middle East, and Africa.
• Entered a supply agreement with Akeso to secure the drug substance needed for clinical trials and future commercial use.
• Initiated collaborations with global institutions through an investigator-sponsored trial program to find more uses for ivonescimab in different tumor types.

What Makes Summit Stand Out

The company uses unique Tetrabody technology to create molecules that bind more strongly to tumors than healthy tissue. This cooperative binding design seeks to increase treatment effectiveness while reducing common side effects.

The Scorecard

• Operating income was -$224.9 million in Q4 2025, down 242.7% from the previous year.
• Net loss reached $219.2 million in Q4 2025, a 258.1% increase in losses year-over-year.
• Operating cash flow was -$100 million in Q4 2025, down 105.4% from Q4 2024.
• Market capitalization was $13.1 billion in Q4 2025, down 0.7% from the prior year.

The Bottom Line

Summit has transitioned from a general infectious disease company into a late-stage oncology developer through a major licensing deal. Its path now depends on the clinical success and regulatory approval of its lead bispecific antibody.